Literature DB >> 28828701

Inherited predisposition to breast and ovarian cancer in non-Jewish populations in Israel.

Jamal Zidan1, Alicia Y Zhou2, Jeroen van den Akker2, Yael Laitman3, Hagit Schayek3, Julia Schnaider1, Eitan Friedman4,5.   

Abstract

PURPOSE: The contribution of genetic factors to cancer in non-Jewish populations in Israel is understudied. Yet the early, mostly premenopausal age at breast cancer diagnosis is suggestive of an inherited predisposition.
METHODS: High-risk cancer cases of non-Jewish origin who were counseled at the Oncogenetics unit, Sheba Medical Center and the oncology institute at the Ziv medical center from January 1, 2000 to December 31 2016 were eligible. DNA extracted from leukocytes was subjected to massive parallel, next-generation sequencing using the Color Genomics platform. Data were analyzed for pathogenic and likely pathogenic mutations using existing pipelines.
RESULTS: Overall, 68 cases, each representing a unique high-risk breast/ovarian family, were genotyped: 32 Druze, 26 Muslim Arabs, and 10 Christian Arabs. Fifty-nine had breast cancer (mean age at diagnosis 42.7 ± 7.6 years), and 9 had ovarian cancer (51.6 ± 9.7 years). Overall three pathogenic mutations one each in BRCA1, PALB2, and BRIP1 genes were detected mostly in Druze families. In addition, 29 variants of unknown significance were also detected, and in 36 cases no sequence variants were noted in any of the genotyped genes.
CONCLUSION: The contribution of the known cancer susceptibility genes to the burden of inherited breast/ovarian cancer predisposition in non-Jews in Israel is modest. Other genes or molecular mechanisms account for the familial breast/ovarian cancer clustering in this population.

Entities:  

Keywords:  Cancer panel testing; Cancer susceptibility genes; Consanguineous marriage; Inherited cancer; Isolated populations; Non-Jewish Israeli populations

Mesh:

Substances:

Year:  2017        PMID: 28828701     DOI: 10.1007/s10549-017-4474-3

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  4 in total

1.  A recurrent pathogenic BRCA2 exon 5-11 duplication in the Christian Arab population in Israel.

Authors:  Hagit Baris-Feldman; Karin Weiss; Gili Reznick Levi; Gal Larom; Vered Ofen Glassner; Nina Ekhilevitch; Nitzan Sharon Swartzman; Tamar Paperna
Journal:  Fam Cancer       Date:  2021-05-17       Impact factor: 2.446

2.  BRIP1, RAD51C, and RAD51D mutations are associated with high susceptibility to ovarian cancer: mutation prevalence and precise risk estimates based on a pooled analysis of ~30,000 cases.

Authors:  Malwina Suszynska; Magdalena Ratajska; Piotr Kozlowski
Journal:  J Ovarian Res       Date:  2020-05-02       Impact factor: 4.234

3.  Summary of BARD1 Mutations and Precise Estimation of Breast and Ovarian Cancer Risks Associated with the Mutations.

Authors:  Malwina Suszynska; Piotr Kozlowski
Journal:  Genes (Basel)       Date:  2020-07-15       Impact factor: 4.096

4.  Racial and ethnic variation in multigene panel testing in a cohort of BRCA1/2-negative individuals who had genetic testing in a large urban comprehensive cancer center.

Authors:  Sushma Tatineni; Meri Tarockoff; Nadine Abdallah; Kristen S Purrington; Hadeel Assad; Rachel Reagle; Nancie Petrucelli; Michael S Simon
Journal:  Cancer Med       Date:  2022-01-17       Impact factor: 4.452

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.